Clinical Trial Update: A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms [Phase 1]

View source ↗

Summary

This clinical trial update announces a Phase 1 study of JNJ-88549968 for CALR-mutated myeloproliferative neoplasms and indicates the trial is currently recruiti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Essential Thrombocythemia
• Myelofibrosis
• Myeloproliferative Neoplasms
• Polycythemia Vera

Drugs mentioned

• JNJ-88549968

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Neoplasms | Phase 1 | Status: RECRUITING